Pfizer's Celebrex Showed Cardiovascular Risk In 1999 Alzheimer's Study
This article was originally published in The Pink Sheet Daily
Executive Summary
A study of celecoxib in Alzheimer's disease patients showed a statistically significant increase in cardiovascular events versus placebo. The study data are posted on PhRMA's clinicalstudyresults.org website, but Public Citizen alleges Pfizer recently revised the posting and questions when the data were submitted to FDA.